Preparation for preventing or treating equine asthma
Inhalation of a VIP receptor agonist like Aviptadil, combined with mucolytic agents, addresses the limitations of glucocorticoids in treating equine asthma by providing sustained relief from inflammation and mucus accumulation, improving lung function and overall health in horses.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Filing Date
- 2025-12-23
- Publication Date
- 2026-07-09
AI Technical Summary
Current treatments for equine asthma, particularly the severe form (RAO), rely on glucocorticoids that provide short-term relief but come with significant side effects and do not address the underlying inflammation or mucus accumulation, leading to frequent relapses.
Inhalation of a vasoactive intestinal peptide (VIP) receptor agonist, such as Aviptadil, which directly targets the airways to reduce inflammation, relax smooth muscles, and clear mucus, potentially combined with a mucolytic agent like N-acetylcysteine, to provide long-term symptom relief.
The VIP receptor agonist effectively reduces airway obstruction and inflammation, improves lung function, and enhances the quality of life for horses with equine asthma, avoiding systemic side effects and reducing relapse rates.
Smart Images
Figure EP2025088965_09072026_PF_FP_ABST